To describe the introduction, uptake, and current use of high-dose (HD) influenza vaccines in Spain and summarize the evidence supporting their broader adoption in adults aged ≥60 years.
Approach:
Narrative Synthesis: A narrative synthesis of clinical evidence and analysis of vaccination strategies implemented across Spanish autonomous communities since the introduction of HD vaccines during the COVID-19 pandemic.
Key Findings:
High-dose influenza vaccines show superior effectiveness in preventing severe outcomes compared to standard-dose vaccines, supported by randomized clinical trials and meta-analyses.
Evidence supports extending HD vaccine use as a population-based strategy for adults aged ≥60 years, aligning with international recommendations.
Uptake of HD vaccines varies across Spanish regions, with some prioritizing institutionalized populations and others including community-dwelling adults.
Interpretation:
Limitations:
Heterogeneous uptake of HD vaccines across different regions may affect overall effectiveness.
The analysis may not capture all factors influencing vaccination strategies.
Conclusion:
The incorporation of HD influenza vaccines marks a significant shift in national vaccination strategies in Spain.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
